Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DEXCOM INCDXCM · Entity 3114 | EVP Global Business Services I | March 10, 2023 | March 14, 2023 |
| ICU MEDICAL INC/DEICUI · Entity 2385 | Director | May 13, 2026 | May 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DEXCOM INC
Report date March 10, 2023 · Filed March 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 208,023 |
Last balance in matching sequence
After 2023-03-10 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2023-03-10 · Disposition to issuer · Disposed 3,604 · Balance 216,088 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: Included in this number are 39,132 unvested restricted stock units. 18,776 granted on March 8, 2023 shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Row 2 · 2023-03-10 · Disposition to issuer · Disposed 4,675 · Balance 211,413 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: Included in this number are 39,132 unvested restricted stock units. 18,776 granted on March 8, 2023 shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Row 3 · 2023-03-10 · Disposition to issuer · Disposed 3,390 · Balance 208,023 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: Included in this number are 39,132 unvested restricted stock units. 18,776 granted on March 8, 2023 shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: Included in this number are 39,132 unvested restricted stock units. 18,776 granted on March 8, 2023 shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024.
ICU MEDICAL INC/DE
Report date May 13, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,004 |
Reported balance
After 2026-05-13 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-13 · Exercise / conversion · Acquired 1,254 · Balance 6,004 F1: These securities are Restricted Stock Units. |
| Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2027-05-13 | Direct | 0 |
Reported balance
After 2026-05-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-13 · Exercise / conversion · Disposed 1,254 · Balance 0 F1: These securities are Restricted Stock Units. F2: There is neither a purchase price nor an exercise price for the Restricted Stock Units. F3: These awards vest on the anniversary of the date of the grant or the following annual stockholder meeting, whichever occurs first. |
| Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2027-05-13 | Direct | 1,475 |
Reported balance
After 2026-05-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-13 · Grant · Acquired 1,475 · Balance 1,475 F1: These securities are Restricted Stock Units. F2: There is neither a purchase price nor an exercise price for the Restricted Stock Units. F3: These awards vest on the anniversary of the date of the grant or the following annual stockholder meeting, whichever occurs first. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are Restricted Stock Units.
F2: There is neither a purchase price nor an exercise price for the Restricted Stock Units.
F3: These awards vest on the anniversary of the date of the grant or the following annual stockholder meeting, whichever occurs first.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 11, 2020 Filed Mar 14, 2020 01:28 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 214 | $245.44 | $52,524.87 |
DisclosureSEC source: 0001093557-20-000104 · edgardoc.xml · nonDerivative · entry 1 Abbey Donald · CIK 0001534342 · EVP Quality and Regulatory Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,543 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $245.2069 to $246.05. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 31,636 restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 08, 2020 Filed Mar 10, 2020 22:57 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 8,811 | $0.00 | $8.81 |
DisclosureSEC source: 0001093557-20-000058 · edgardoc.xml · nonDerivative · entry 1 Abbey Donald · CIK 0001534342 · EVP Quality and Regulatory Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,757 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 31,636 restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 23:20 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,990 | $221.16 | $661,257.34 |
DisclosureSEC source: 0001093557-19-000245 · edgardoc.xml · nonDerivative · entry 4 Abbey Donald · CIK 0001534342 · EVP Quality and Regulatory Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,946 F1 · shares: On August 23, 2019, Mr. Abbey adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Abbey. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $221.00 to $221.86. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 38,823 restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 4,585 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 23:20 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 4,259 | $220.50 | $939,106.94 |
DisclosureSEC source: 0001093557-19-000245 · edgardoc.xml · nonDerivative · entry 3 Abbey Donald · CIK 0001534342 · EVP Quality and Regulatory Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,936 F1 · shares: On August 23, 2019, Mr. Abbey adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Abbey. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $220.00 to $220.99. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 38,823 restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 4,585 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 23:20 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,037 | $219.65 | $667,067.94 |
DisclosureSEC source: 0001093557-19-000245 · edgardoc.xml · nonDerivative · entry 2 Abbey Donald · CIK 0001534342 · EVP Quality and Regulatory Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,195 F1 · shares: On August 23, 2019, Mr. Abbey adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Abbey. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $219.00 to $219.99. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 38,823 restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 4,585 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 23:20 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,318 | $218.43 | $287,896.80 |
DisclosureSEC source: 0001093557-19-000245 · edgardoc.xml · nonDerivative · entry 1 Abbey Donald · CIK 0001534342 · EVP Quality and Regulatory Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,232 F1 · shares: On August 23, 2019, Mr. Abbey adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Abbey. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $217.98 to $218.81. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 38,823 restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 4,585 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| September 09, 2019 Filed Sep 12, 2019 01:30 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 5,525 | $150.11 | $829,363.83 |
DisclosureSEC source: 0001093557-19-000197 · edgardoc.xml · nonDerivative · entry 2 Abbey Donald · CIK 0001534342 · EVP Quality and Regulatory Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,550 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · balance_after: Included in this number are 38,823 restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 4,585 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| September 09, 2019 Filed Sep 12, 2019 01:30 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 318 | $145.39 | $46,234.53 |
DisclosureSEC source: 0001093557-19-000197 · edgardoc.xml · nonDerivative · entry 1 Abbey Donald · CIK 0001534342 · EVP Quality and Regulatory Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,075 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $145.33 to $145.47. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected F3 · balance_after: Included in this number are 38,823 restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 4,585 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| June 03, 2019 Filed Jun 4, 2019 21:37 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 9,030 | $121.08 | $1,093,352.40 |
DisclosureSEC source: 0001093557-19-000144 · edgardoc.xml · nonDerivative · entry 1 Abbey Donald · CIK 0001534342 · EVP Quality and Regulatory Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,393 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 49,825 restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 9,170 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| May 15, 2019 Filed May 16, 2019 16:29 UTC | ICU MEDICAL INC/DE ICUI · Entity 2385 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,253 | $0.00 Strike: $225.27 | $0.00 |
DisclosureSEC source: 0001209191-19-030246 · doc4.xml · derivative · entry 4 Abbey Donald · CIK 0001534342 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,253 Underlying: Common Stock · 1,253 shares Expires 2029-05-15 Read SEC document |
| May 15, 2019 Filed May 16, 2019 16:29 UTC | ICU MEDICAL INC/DE ICUI · Entity 2385 | GrantCommon Stock · Derivative | 378 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-030246 · doc4.xml · derivative · entry 3 Abbey Donald · CIK 0001534342 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378 Underlying: Common Stock · 378 shares Expires 2020-05-15 F1 · security: These securities are Restricted Stock Units. F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the Restricted Stock Units. F3 · derivative.exercise_date: These Restricted Stock Units vest on the anniversary of the date of the award. Read SEC document |
| May 15, 2019 Filed May 16, 2019 16:29 UTC | ICU MEDICAL INC/DE ICUI · Entity 2385 | Exercise / conversionCommon Stock · Derivative | 315 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-030246 · doc4.xml · derivative · entry 2 Abbey Donald · CIK 0001534342 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 315 shares Expires 2019-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These securities are Restricted Stock Units. F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the Restricted Stock Units. F3 · derivative.exercise_date: These Restricted Stock Units vest on the anniversary of the date of the award. Read SEC document |
| May 15, 2019 Filed May 16, 2019 16:29 UTC | ICU MEDICAL INC/DE ICUI · Entity 2385 | Exercise / conversionCommon Stock | 315 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-030246 · doc4.xml · nonDerivative · entry 1 Abbey Donald · CIK 0001534342 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 22:59 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 6,039 | $142.79 | $862,322.10 |
DisclosureSEC source: 0001093557-19-000076 · edgardoc.xml · nonDerivative · entry 2 Abbey Donald · CIK 0001534342 · EVP Quality and Regulatory Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,423 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 68,158 restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 9,170 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 18,333 of which were granted on May 31, 2016 and shall vest through May 31, 2019. Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 22:59 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,614 | $142.79 | $230,466.61 |
DisclosureSEC source: 0001093557-19-000076 · edgardoc.xml · nonDerivative · entry 1 Abbey Donald · CIK 0001534342 · EVP Quality and Regulatory Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,462 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 68,158 restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 9,170 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 18,333 of which were granted on May 31, 2016 and shall vest through May 31, 2019. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 00:25 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 14,987 | $0.00 | $14.99 |
DisclosureSEC source: 0001093557-19-000047 · wf-form4_155235030701474.xml · nonDerivative · entry 1 Abbey Donald · CIK 0001534342 · EVP Quality and Regulatory Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,076 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. F2 · balance_after: Included in this number are 68,158 restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 9,170 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 18,333 of which were granted on May 31, 2016 and shall vest through May 31, 2019. Read SEC document |
| November 09, 2018 Filed Nov 14, 2018 01:13 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 6,900 | $149.91 | $1,034,361.75 |
DisclosureSEC source: 0001093557-18-000234 · edgardoc.xml · nonDerivative · entry 3 Abbey Donald · CIK 0001534342 · EVP, Quality & Regulatory Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,089 F1 · shares: On September 13, 2018, Mr. Abbey adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Abbey. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $149.28 to $150.11. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected F3 · balance_after: Included in this number are 70,590 restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 18,333 of which were granted on May 31, 2016 and shall vest through May 31, 2019. Read SEC document |
| November 09, 2018 Filed Nov 14, 2018 01:13 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,900 | $148.66 | $282,459.51 |
DisclosureSEC source: 0001093557-18-000234 · edgardoc.xml · nonDerivative · entry 2 Abbey Donald · CIK 0001534342 · EVP, Quality & Regulatory Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,989 F1 · shares: On September 13, 2018, Mr. Abbey adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Abbey. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $148.22 to $149.01. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected F3 · balance_after: Included in this number are 70,590 restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 18,333 of which were granted on May 31, 2016 and shall vest through May 31, 2019. Read SEC document |
| November 09, 2018 Filed Nov 14, 2018 01:13 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,750 | $147.62 | $258,337.98 |
DisclosureSEC source: 0001093557-18-000234 · edgardoc.xml · nonDerivative · entry 1 Abbey Donald · CIK 0001534342 · EVP, Quality & Regulatory Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,889 F1 · shares: On September 13, 2018, Mr. Abbey adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Abbey. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $147.22 to $148.11. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected F3 · balance_after: Included in this number are 70,590 restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 18,333 of which were granted on May 31, 2016 and shall vest through May 31, 2019. Read SEC document |
| September 10, 2018 Filed Sep 13, 2018 01:19 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,303 | $143.76 | $331,068.23 |
DisclosureSEC source: 0001093557-18-000194 · edgardoc.xml · nonDerivative · entry 1 Abbey Donald · CIK 0001534342 · EVP, Quality & Regulatory Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,639 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 70,590 restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 18,333 of which were granted on May 31, 2016 and shall vest through May 31, 2019. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 21:49 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 9,011 | $88.10 | $793,869.10 |
DisclosureSEC source: 0001093557-18-000119 · edgardoc.xml · nonDerivative · entry 1 Abbey Donald · CIK 0001534342 · EVP, Quality & Regulatory Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,942 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 75,175 restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 18,340 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 18,333 of which were granted on May 31, 2016 and shall vest through May 31, 2019. Read SEC document |
| May 15, 2018 Filed May 17, 2018 20:59 UTC | ICU MEDICAL INC/DE ICUI · Entity 2385 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,163 | $0.00 Strike: $269.80 | $0.00 |
DisclosureSEC source: 0001209191-18-031017 · doc4.xml · derivative · entry 2 Abbey Donald · CIK 0001534342 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,163 Underlying: Common Stock · 1,163 shares Expires 2028-05-15 Read SEC document |
| May 15, 2018 Filed May 17, 2018 20:59 UTC | ICU MEDICAL INC/DE ICUI · Entity 2385 | GrantCommon Stock · Derivative | 315 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-031017 · doc4.xml · derivative · entry 1 Abbey Donald · CIK 0001534342 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315 Underlying: Common Stock · 315 shares Expires 2019-05-15 F1 · security: These securities are Restricted Stock Units. F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the Restricted Stock Units. F3 · derivative.exercise_date: These Restricted Stock Units vest on the anniversary of the date of the award. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 01:02 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 3,275 | $60.73 | $198,892.72 |
DisclosureSEC source: 0001093557-18-000055 · edgardoc.xml · nonDerivative · entry 1 Abbey Donald · CIK 0001534342 · EVP, Quality & Regulatory Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,953 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 93,508 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 18,340 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 36,666 of which were granted on May 31, 2016 and shall vest through May 31, 2019. Read SEC document |
| March 08, 2018 Filed Mar 13, 2018 01:34 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 38,502 | $0.00 | $38.50 |
DisclosureSEC source: 0001093557-18-000041 · edgardoc.xml · nonDerivative · entry 1 Abbey Donald · CIK 0001534342 · EVP, Quality & Regulatory Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,228 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. F2 · balance_after: Included in this number are 93,508 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 18,340 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 36,666 of which were granted on May 31, 2016 and shall vest through May 31, 2019. Read SEC document |
| June 01, 2017 Filed Jun 6, 2017 00:02 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 7,784 | $66.38 | $516,706.59 |
DisclosureSEC source: 0001093557-17-000135 · edgardoc.xml · nonDerivative · entry 1 Abbey Donald · CIK 0001534342 · EVP Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,726 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 64,176 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 36,666 of which were granted on May 31, 2016 and shall vest through May 31, 2019. Read SEC document |
| March 08, 2017 Filed Mar 11, 2017 01:46 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 27,510 | $0.00 | $27.51 |
DisclosureSEC source: 0001093557-17-000061 · edgardoc.xml · nonDerivative · entry 1 Abbey Donald · CIK 0001534342 · EVP Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,510 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. F2 · balance_after: Included in this number are 82,510 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 55,000 of which were granted on May 31, 2016 and shall vest through May 31, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.